Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva
Shares of Axsome Therapeutics AXSM jumped 20.2% on Monday after the company announced that it has entered into a settlement agreement with Teva Pharmaceuticals TEVA related to patents for the psychiatry drug,
Shares in Biopharma Firm Axsome Surge Over 20% After Settling Teva Patent Dispute
Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute with peer Teva
Axsome stock target raised to $190 on Teva litigation resolution
TD Cowen adjusted its outlook on Axsome Therapeutics (NASDAQ:AXSM), a $6.16 billion market cap company, by increasing the price target to $190 from the previous $155, while maintaining a Buy rating on the company's shares.
Axsome shares jump as settlement will keep Teva's Auvelity generic off the market until 2038
With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press release. Entrance of the generic will be delayed by an additional six months, until March 31, 2039, if Axsome gains an FDA pediatric exclusivity extension for its treatment.
Axsome settles Auvelity patent litigation with Teva
Axsome Therapeutics (AXSM) stock rallied 15% on news the company has settled patent litigation with Teva (TEVA) over a proposed generic version of Auvelity. Read more here.
Axsome secures top drug’s future with Teva patent settlement
Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy of Auvelity from entering the U.S. market until at least 2038.
Axsome Therapeutics Shares Rise After Agreement with Teva Pharmaceuticals Ends Litigation
Under the agreement, Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric exclusivity is granted for Auvelity, or on or after Sept. 30, 2039, if no pediatric exclusivity is granted.
Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation
Under the terms of the settlement agreement, Axsome will grant Teva a license to sell its generic version of AUVELITY beginning on or after March 31, 2039, if pediatric exclusivity is granted for AUVELITY,
Axsome Therapeutics stock rises on patent litigation settlement
Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) surged 15% following the announcement of a settlement agreement with Teva Pharmaceuticals that resolves patent litigation over its flagship product, AUVELITY®.
Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'
Axsome Therapeutics, Inc. (NASDAQ:AXSM) signed a settlement agreement with Teva Pharmaceuticals Inc (NYSE:TEVA). The ...
Why Axsome Therapeutics Stock Is Skyrocketing Today
Shares of Axsome Therapeutics ( AXSM 20.22%) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, ...
Axsome Therapeutics price target raised to $167 from $143 at BofA
BofA analyst Jason Gerberry raised the firm’s price target on Axsome Therapeutics (AXSM) to $167 from $143 and keeps a Buy rating on the shares ...
FiercePharma11d
Axsome secures hard-fought FDA nod for rapid-acting migraine drug Symbravo
Axsome Therapeutics has finally jumped all the hurdles in a challenging regulatory saga, winning approval for its oral migraine drug Symbravo. The rapid-acting treatment is approved for the acute ...